Shanghai Junshi Biosciences Second Quarter 2024 Earnings: CN¥0.36 loss per share (vs CN¥0.46 loss in 2Q 2023)
Shanghai Junshi Biosciences (HKG:1877) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥405.3m (down 2.2% from 2Q 2023).
- Net loss: CN¥361.9m (loss narrowed by 20% from 2Q 2023).
- CN¥0.36 loss per share (improved from CN¥0.46 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai Junshi Biosciences Earnings Insights
Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Hong Kong.
Performance of the Hong Kong Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Shanghai Junshi Biosciences that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:1877
Shanghai Junshi Biosciences
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People’s Republic of China.
Excellent balance sheet and slightly overvalued.